Compare Organon & Co. Common Stock (OGN) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs abrdn Physical Palladium Shares ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while abrdn Physical Palladium Shares ETF trades at $20.17 (market cap $602.28M). The key difference: Organon & Co. Common Stock is far larger — about 6× abrdn Physical Palladium Shares ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while abrdn Physical Palladium Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and abrdn Physical Palladium Shares ETF for 34 Days on average.
| OGN | PALL | |
|---|---|---|
Market Cap | $3.62B | $602.28M |
Volume | 2,892,999 | 499,677 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $13.81 | $37.18 |
52-Week Low | $5.70 | $19.83 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PALL trades at $20.38, down 1.12% with a bearish technical signal from moving averages. The ETF shows oversold conditions with RSI readings below 30, while palladium prices remain 47% below January 2026 highs. Recent news highlights potential catch-up opportunities as platinum and palladium have lagged the broader precious metals rally.
The outlook suggests contrarian opportunity as palladium approaches technical support levels, though fundamental data remains limited. Key risks include continued commodity price pressure and industrial demand uncertainty, while potential catalysts include supply constraints and renewed institutional interest in undervalued precious metals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
